Irinotecan Hydrochloride Accord Healthcare Ireland

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hydrochloride Accord Healthcare Ireland, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients.

GNH USA supplies Irinotecan Hydrochloride Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable oncology medicines through its global network of regulatory‑approved distributors.

Irinotecan is a topoisomerase I inhibitor used primarily in colorectal cancer treatment regimens.

Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based chemotherapy. Advanced colorectal carcinoma: reduces tumor progression in patients with refractory disease. Colorectal cancer (first‑line setting): incorporated into combination regimens to increase overall response rates.

Irinotecan therapy is associated with a range of adverse reactions.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea: may occur during or after infusion. - Fatigue: generalised tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenia with infection: can be life‑threatening. - Febrile neutropenia: fever accompanying low neutrophil counts. - Severe colitis/diarrhea: may lead to dehydration and electrolyte imbalance.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Blood count monitoring: perform regular CBC to detect neutropenia early. - Liver function assessment: evaluate hepatic enzymes as irinotecan is metabolised hepatically. - Bowel obstruction risk: avoid use in patients with known gastrointestinal obstruction. - Hypersensitivity: discontinue if allergic reactions such as rash or anaphylaxis occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase irinotecan exposure and toxicity. - Concurrent myelosuppressive agents: amplify risk of severe neutropenia. - Cholinesterase inhibitors: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce irinotecan effectiveness. - UGT1A1 inhibitors (e.g., atazanavir): modestly raise SN‑38 levels. - Anticoagulants (e.g., warfarin): may increase bleeding tendency.